1. Home
  2. RGNX vs MYI Comparison

RGNX vs MYI Comparison

Compare RGNX & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGNX
  • MYI
  • Stock Information
  • Founded
  • RGNX 2008
  • MYI 1992
  • Country
  • RGNX United States
  • MYI United States
  • Employees
  • RGNX N/A
  • MYI N/A
  • Industry
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • MYI Investment Bankers/Brokers/Service
  • Sector
  • RGNX Health Care
  • MYI Finance
  • Exchange
  • RGNX Nasdaq
  • MYI Nasdaq
  • Market Cap
  • RGNX 661.2M
  • MYI 736.5M
  • IPO Year
  • RGNX 2015
  • MYI N/A
  • Fundamental
  • Price
  • RGNX $12.77
  • MYI $11.04
  • Analyst Decision
  • RGNX Strong Buy
  • MYI
  • Analyst Count
  • RGNX 7
  • MYI 0
  • Target Price
  • RGNX $30.00
  • MYI N/A
  • AVG Volume (30 Days)
  • RGNX 601.4K
  • MYI 256.7K
  • Earning Date
  • RGNX 11-06-2025
  • MYI 01-01-0001
  • Dividend Yield
  • RGNX N/A
  • MYI 4.81%
  • EPS Growth
  • RGNX N/A
  • MYI N/A
  • EPS
  • RGNX N/A
  • MYI N/A
  • Revenue
  • RGNX $155,782,000.00
  • MYI N/A
  • Revenue This Year
  • RGNX $198.02
  • MYI N/A
  • Revenue Next Year
  • RGNX $2.67
  • MYI N/A
  • P/E Ratio
  • RGNX N/A
  • MYI N/A
  • Revenue Growth
  • RGNX 74.95
  • MYI N/A
  • 52 Week Low
  • RGNX $5.04
  • MYI $9.32
  • 52 Week High
  • RGNX $13.93
  • MYI $11.70
  • Technical
  • Relative Strength Index (RSI)
  • RGNX 58.75
  • MYI 57.78
  • Support Level
  • RGNX $12.66
  • MYI $10.95
  • Resistance Level
  • RGNX $13.93
  • MYI $11.05
  • Average True Range (ATR)
  • RGNX 0.72
  • MYI 0.08
  • MACD
  • RGNX -0.04
  • MYI -0.02
  • Stochastic Oscillator
  • RGNX 61.82
  • MYI 42.86

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

About MYI Blackrock MuniYield Quality Fund III Inc

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.

Share on Social Networks: